DELEXs unwavering dedication to addressing the crucial needs of critical care within the healthcare landscape has intensified further and is set to propel DELEX’s growth trajectory and expand its reach ensuring enhanced accessibility to essential healthcare solutions across the country.
J. de Ruyter Oroceo, CEO and Chairman of the Board of DELEX, stated, Through innovative, affordable, and essential products, DELEX is devoted to its goal of meeting the Gaps in Critical Care by offering solutions for patients in Intensive Care Units (ICUs).
Currently, the companys products lineup comprises more than thirty (30) trusted brands, the majority of which are recognized for their superior quality, efficacy, affordability, and accessibility. DELEXs commitment not only serves a niche market in the Philippines, but also ensures the caliber and dominance of its products in the ICU medication industry, paving the way for continuous improvement and growth in the years to come.
DELEX distributes top-of-the-line products to over 600 hospitals, distributors, and diagnostic clinics, making it the third largest Filipino-owned pharma and medical device company in the hospital channel in the Philippines. These products undergo rigorous regulatory testing and are sourced from reputable manufacturers certified with World Health Organization Good Manufacturing Practices (WHO GMP) to ensure reliable quality for ICU patients. The companys product line covers critical care, anti-infective, anesthesia, oncology, medical device, and womens health. DELEXs power brands are the following:
The critical care portfolio has been instrumental in helping healthcare practitioners save the lives of numerous Intensive Care Unit (ICU) patients in primary to tertiary hospitals across both private and government sectors. These products include HUMAL, a blood substitute and plasma protein fraction solution manufactured by Fortune Global 500 company in India, and TOTILAC, which is the only premixed hypertonic lactate solution in three percent (3%) preparation available in the local market. The company also markets DOBULEX and NOREPIN, which had been the leading generic Dobutamine and norepinephrine solutions in the country. Lastly, Nicardilex, a new product in the market offered by DELEX, immediately became the second-leading Nicardipine brand due to its affordability.
DELEXs continuous innovation has revolutionized the healthcare industry through its effective and high-quality products for infections. Four (4) antibacterial products are being offered by DELEX in the Philippine market which are all premium, affordable, and widely-used brands in ICUs. These anti-infective brands are DELEXIGYL (Metronidazole), CEFTREX (Ceftriaxone), CEFTAZIN (Ceftazidime), and AXAZOLID (Linezolid). In addition to anti-infective products, DELEX also offers FUNGINIL, an antifungal product that is the first branded generic Fluconazole available in the Philippines. With the Philippines’ anti-infective agents market projected to reach USD 1.5 billion by 2032, the company will continue to strengthen this portfolio by expanding its product pipeline.
The company markets six (6) anesthesia products, most of which are more affordable than the leading brands in the market. One of the prominent anesthesia products of DELEX, penetrating 90% of the hospitals across the country, is IFIMOL, a premier brand of paracetamol. In 2018, IFIMOL was included in the IQVIA Report as one of the Top 200 Hospital Ethical Products. Another notable product is INTRAFEN, the pioneering and sole Ibuprofen brand in I.V. preparation introduced in the Philippines in August 2018.
According to a report by the Philippine Statistics Authority (PSA), cancer was the second leading cause of mortality in 2022. This highlights the significant impact the oncology market position will have on DELEXs business opportunities while reinforcing its mission to address gaps in critical care. In response to the rising cancer cases in the country, DELEX has launched five products to provide effective solutions: IFOSFAMIDE (Fosfalex), FLUOROURACIL (Flouracilex), PACLITAXEL (Paclitex), DOXORUBICIN (D-xobin), and DOCETAXEL (Docelex).
In a proactive effort towards advancing its commitment to serve ICU patients not only within the Philippines but also on a global scale, DELEX has formulated an expansion plan. This includes the development of an expanded product line, acquisition of product and distribution rights both locally and internationally, investments in healthcare product manufacturing and service provision, and the amplification of Delex Pharmacy. The augmentation plan, which synergistically aligns with the promising growth trajectory of the Philippine healthcare industry and is bolstered by the strategic partnership with BNCM, charting a course for incremental success. This not only addresses critical care gaps, but also promises substantial returns for DELEX’s shareholders and investors.
DELEX is committed to delivering innovation, affordability, and accessibility within the Philippine pharmaceutical and medical device landscapes. As a result, the company has secured strategic partners in the healthcare sector to address the needs of critically ill patients. The substantial growth and success the company has to offer, through its successful partnerships and prominent and leading products, present an exceptional opportunity for investors, shareholders, and partners to not only gain substantial returns but also drive meaningful impact in the healthcare industry by contributing to the wider distribution of ICU products and development of new solutions for critical care. The investments will play an crucial role in catalyzing the development and execution of expansion plans for DELEX which will substantially benefit the ICU patients across the Philippines and globally.
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
DELEX is a Delaware-registered company, and the holding company of DLX Holdings, Inc. (DLX). DLX is a Philippine-based parent company that holds a 60% controlling interest in Delex Pharma International, Inc. an ISO 9001-2015 Certified company, which also holds a controlling interest in JMN Brother’s Pharma Limited, Inc. DLX and its subsidiaries are involved in the development and distribution of pharmaceutical and healthcare products in the Philippines.
For more information, visit: https://delexhealth.com
